A panel of experts on nasopharyngeal carcinoma review patient cases and provide comprehensive insights on treatment practices.
EP. 1: Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach
Experts on nasopharyngeal carcinoma (NPC) provide an overview of the disease, highlighting its incidence, how it’s differentiated from other head and neck cancers, and the benefits of multidisciplinary care.
EP. 2: Current Guidelines for Managing Nasopharyngeal Carcinoma
Shravan Kandula, MD, reviews the current guidelines for the treatment of patients with nasopharyngeal carcinoma.
EP. 3: Overview of the JUPITER and POLARIS-2 Trials
Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.
EP. 4: Value of PD-L1 Biomarker in NPC
A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.
EP. 5: Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab
Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.
EP. 6: Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors
Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.
Frontline Amivantamab/Lazertinib Combo Shows Trend of OS Benefit in Advanced EGFR+ NSCLC
TROP2 Membrane Ratio Effectively Predicts Dato-DXd Outcomes in NSCLC
Dr Sen on Interim IDeate-Lung01 Data in Extensive-Stage SCLC
Patient-Level Data Support Perioperative Nivolumab Use in Resectable NSCLC